Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors – Promising Therapy in the field of Oncology

Cyclin-Dependent Kinases (CDKs) are a family of protein kinases and considered as the key regulators of the cell cycle. The discovery of CDKs is a result of the increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. They are involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. The major focus is to develop first generation CDK 4/6 inhibitors and then proceed to second generation as they are more efficient and less toxic antineoplastic agents.

Due to promising results shown by this therapy in the clinical phases the pipeline of top pharmaceutical companies are highly active with drugs targeting the CDK Inhibitors. Upcoming drugs are expected to highly influence the future therapeutic market as per the latest report.

According to the American Cancer Society, around 25% breast cancer cases have been reported globally so far in 2017 with around 252,710 cases of invasive breast cancer and 63,410 of non-invasive breast cancer in US. These stats are providing a clear idea that oncology needs more promising and effective treatment options.

According to the latest report of DelveInsight, “Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors Competitive Landscape, Market and Pipeline Analysis 2017”, pipeline scenario in this domain is also highly active with about 8% of the total pipeline products in phase III and 31% in phase II like Alvocidib (Sumitomo dainippon pharma), AT7519 (Astex pharmaceuticals) and many others. Out of the 2 marketed products, Pfizer’s Ibrance is already a blockbuster drug by taking the early mover advantage in the market but now it will face tough competition from Kisqali. Novartis drug Kisqali is also expected to occupy large market share and become a blockbuster due to the limited number of treatment options. The CDK market is about to see the maximum competition of all time due to the expected release of pipeline products. Many companies have collaborated together to fuel their R&D process and accelerate the pace of their drug launch in the market.

The latest report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house Forecast model analysis to provide cutting-edge information. It provides detailed insight into the global pipeline scenario for CDK inhibitors, products, and associated companies information. Complete coverage of pipeline products with detailed pipeline and marketed product profiling. Information about inactive and dormant products is also covered in this report.

Get a free Sample Page: https://www.delveinsight.com/report-store/cyclin-dependent-kinase-cdk-inhibitors-competitive-landscape-market-and-pipeline-analysis

Reasons to buy:

  • The report provides competitive pipeline landscape of Cyclin-Dependent Kinase Inhibitors.
  • The report provides information about the pipeline products, pipeline product profiling, collaborations, and acquisitions.
  • The report covers the Current Prominent Research Areas and Key Players.
  • Pipeline product coverage based on various stages of development ranging from discovery stage till late stage products.
  • The report provides complete information about the market drivers, market barriers and possible opportunities.

Companies covered:

  • Novartis
  • Pfizer
  • Sumitomo dainippon pharma
  • Astex pharmaceuticals
  • Bayer
  • AstraZenca
  • Merck
  • Roche Pharmaceuticals

Table of Contents

  • Active Pipeline Coverage by Indication
  • Overview
  • Mechanism of Action
  • CDK4/6 as Anticancer Drugs
  • CDK 4/6 Inhibitors in Cancer Treatment
  • Marketed Drugs
  • IBRANCE: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities
  • IBRANCE Sales
  • Ibrance-Regulatory Milestones
  • KISQALI: Novartis
  • Product Description
  • Research and Development
  • Product Development Activities
  • KISQALI Forecasted Sales
  • Kisqali Regulatory Milestones
  • Comparative Analysis
  • Patent Analysis
  • Pipeline Therapeutics
  • Comparative Analysis
  • Late Stage Products (Filed)
  • Comparative Analysis
  • Abemaciclib: Eli Lilly
  • Product Description
  • Research and Development
  • Product Development Activities
  • Abemaciclib Forecasted Sales
  • Abemaciclib – Regulatory Milestones
  • Mid Stage Products (Phase II)
  • Comparative Analysis
  • Alvocidib: Sumitomo Dainippon Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
  • AT7519: Astex
  • Product Description
  • Research and Development
  • Product Development Activities
  • Trilaciclib: G1 Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
  • Milciclib: Triziana Life Sciences
  • Product Description
  • Research and Development
  • Product Development Activities
  • MM-D37K: MetaMax
  • Product Description
  • Research and Development
  • Product Development Activities
  • Early Stage Products (Phase I)
  • Comparative Analysis
  • FLX925: FLXBIO
  • Product Description
  • Product Development Activities
  • G1T38: G1 Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
  • SHR6390: Jiangsu HengRui Medicine
  • Product Description
  • Research and Development
  • TG-02: Tragara
  • Product Description
  • Research and Development
  • Product Development Activities
  • P1446A-05: Presage Biosciences
  • Product Description
  • Research and Development
  • Product Development Activities
  • Pre-clinical Stage Products
  • Comparative Analysis
  • VS2-370: ViroStatics
  • Product Description
  • Research and Development
  • Product Development Activities
  • BPI-1178: BetaPharma
  • Product Description
  • ON 123300: Onconova
  • Product Description
  • Research and Development
  • Therapeutic Assessment: Active Products
  • Assessment by Monotherapy Products
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Stage and Molecule Type
  • Discontinued Products
  • Comparative Analysis
  • AG-024322: Pfizer
  • Product Description
  • Research and Development
  • AZD5438: AstraZeneca
  • Product Description
  • Research and Development
  • PHA-793887: Nerviano Medical Sciences
  • Product Description
  • Research and Development
  • P276-00: Piramal Enterprises
  • Product Description
  • Research and Development
  • Roniciclib: Bayer
  • Product Description
  • Research & Development
  • Dormant Products
  • Comparative Analysis
  • CINK4: Merck
  • Product Description
  • Research and Development
  • R547: Roche Pharmaceuticals
  • Product Description
  • Research and Development
  • Drivers and Barriers
  • Appendix